Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:13
Pelthos Therapeutics Shareholders Equity (Quarterly) : -1.501M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.501M |
| March 31, 2026 | 19.27M |
| December 31, 2025 | 38.88M |
| September 30, 2025 | 58.25M |
| June 30, 2025 | -4.196M |
| March 31, 2025 | -4.196M |
| September 30, 2024 | -1.428M |
| Date | Value |
|---|---|
| June 30, 2024 | -0.1825M |
| March 31, 2024 | 1.130M |
| December 31, 2023 | -6.445M |
| September 30, 2023 | -5.905M |
| June 30, 2023 | -4.901M |
| March 31, 2023 | -4.401M |
| December 31, 2022 | -3.706M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | 22.58M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 137.36M |
| Total Liabilities (Quarterly) | 138.86M |
| Debt to Equity Ratio | -48.71 |
| Current Ratio | 1.982 |
| Net Debt Paydown Yield | -13.44% |